Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Menu

    Zilebesiran

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Roche, Alnylam to Initiate Phase 3 Trial of Zilebesiran
    Roche, Alnylam to Initiate Phase 3 Trial of Zilebesiran

    31 Aug 2025

    // PRESS RELEASE

    https://www.roche.com/media/releases/med-cor-2025-08-30

    PRESS RELEASE
    31 Aug 2025
    Share Share
    Chugai in-licenses RNAi therapeutic zilebesiran for hyp.high cardiovascular risk
    Chugai in-licenses RNAi therapeutic zilebesiran for hyp.high cardiovascular risk

    20 Apr 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=168662&sid=2

    PHARMABIZ
    20 Apr 2024
    Share Share
    Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran
    Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran

    07 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240407631982/en

    BUSINESSWIRE
    07 Apr 2024
    Share Share
    Alnylam to Webcast to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran
    Alnylam to Webcast to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran

    20 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240320967622/en

    BUSINESSWIRE
    20 Mar 2024
    Share Share
    Roche, Alnylam say blood pressure drug succeeds in mid-stage trial
    Roche, Alnylam say blood pressure drug succeeds in mid-stage trial

    06 Mar 2024

    // BIOPHARMA DIVE

    https://www.biopharmadive.com/news/alnylam-roche-hypertension-drug-study-results-zilebesiran/709303/

    BIOPHARMA DIVE
    06 Mar 2024
    Share Share
    Alnylam Reports Positive Results from Phase 2 Dose-Ranging Study of Zilebesiran
    Alnylam Reports Positive Results from Phase 2 Dose-Ranging Study of Zilebesiran

    07 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230907817269/en

    BUSINESSWIRE
    07 Sep 2023
    Share Share